Zaltrap (ziv-aflibercept) Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

March 2016

ADVERSE REACTIONS

Post Marketing Experience

Musculoskeletal and connective tissue disorders:

Osteonecrosis...

Source: Drugs.com - Labeling Changes - March 1, 2016 Category: Drugs & Pharmacology Source Type: alerts